Collectively, these data reveal that anti-TIGIT treatment during CA sepsis was associated with a reversal of immune cell loss and a decrease in the frequency of PD-1+ Treg and Teff in hosts with preexisting malignancy. The gene discussed is PDCD1; the disease is Sepsis.